Literature DB >> 24238278

Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction.

Karlien Peeters1, Arun Sahai, Dirk De Ridder, Frank Van Der Aa.   

Abstract

OBJECTIVE: To report our long-term experience of sacral neuromodulation (SNM) for various lower urinary tract dysfunctions but with a focus on efficacy, safety, re-interventions and degree of success. PATIENTS AND METHODS: This is a single tertiary referral centre study that included 217 patients (86% female) who received an implantable pulse generator (IPG) (Interstim™, Medtronic, Minneapolis, USA) between 1996 and 2010. Success was considered if the initial ≥50% improvement in any of primary voiding diary variables persisted compared with baseline, but was further stratified.
RESULTS: The mean duration of follow-up was 46.88 months. Success and cure rates were ≈70% and 20% for urgency incontinence, 68% and 33% for urgency frequency syndrome and 73% and 58% for idiopathic retention. In those patients with an unsuccessful therapy outcome, the mean time to failure was 24.6 months after implantation. There were 88 (41%) patients who had at least one device or treatment related surgical re-intervention. The re-intervention rate was 1.7 per patient with most of them (47%) occurring ≤2 years of follow-up.
CONCLUSIONS: SNM appears effective in the long-term with a success rate after definitive IPG implant of ≈70% and complete cure rates ranging between 20% and 58% depending on indication. Patients with idiopathic retention appear to do best. The re-intervention rate is high with most occurring ≤2 years of implantation. It is likely that with the newer techniques used, efficacy and re-intervention rates will improve.
© 2013 The Authors. BJU International © 2013 BJU International.

Entities:  

Keywords:  Fowler's syndrome; Interstim™; idiopathic retention; lower urinary tract dysfunction; overactive bladder; sacral neuromodulation; urgency frequency syndrome; urgency incontinence; voiding dysfunction

Mesh:

Year:  2014        PMID: 24238278     DOI: 10.1111/bju.12571

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  21 in total

Review 1.  Role of sacral neuromodulation in modern urogynaecology practice: a review of recent literature.

Authors:  Samina Tahseen
Journal:  Int Urogynecol J       Date:  2018-01-04       Impact factor: 2.894

Review 2.  Female Bladder Outlet Obstruction.

Authors:  Daniel S Hoffman; Victor W Nitti
Journal:  Curr Urol Rep       Date:  2016-04       Impact factor: 3.092

Review 3.  Percutaneous tibial nerve stimulation and sacral neuromodulation: an update.

Authors:  Priyanka Gupta; Michael J Ehlert; Larry T Sirls; Kenneth M Peters
Journal:  Curr Urol Rep       Date:  2015-02       Impact factor: 3.092

4.  Adverse events of sacral neuromodulation for fecal incontinence reported to the federal drug administration.

Authors:  Klaus Bielefeldt
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-05-06

5.  [Therapy of overactive bladder (OAB)].

Authors:  M Kurosch; R Mager; K Gust; M Brandt; H Borgmann; A Haferkamp
Journal:  Urologe A       Date:  2015-04       Impact factor: 0.639

Review 6.  Electrical neuromodulation in the management of lower urinary tract dysfunction: evidence, experience and future prospects.

Authors:  Alejandro Abello; Anurag K Das
Journal:  Ther Adv Urol       Date:  2018-02-22

Review 7.  Bladder outlet obstruction in women: functional causes.

Authors:  Ashley B King; Howard B Goldman
Journal:  Curr Urol Rep       Date:  2014-09       Impact factor: 3.092

Review 8.  Management of Postoperative Lower Urinary Tract Symptoms (LUTS) After Pelvic Organ Prolapse (POP) Repair.

Authors:  Annie Chen; Brian McIntyre; Elise J B De
Journal:  Curr Urol Rep       Date:  2018-07-24       Impact factor: 3.092

Review 9.  [Sacral neuromodulation in under- and overactive detrusor-quo vadis? : Principles and developments].

Authors:  F Girtner; M Burger; R Mayr
Journal:  Urologe A       Date:  2019-06       Impact factor: 0.639

10.  Underactive Bladder: Clinical Features, Urodynamic Parameters, and Treatment.

Authors:  Nathan Hoag; Johan Gani
Journal:  Int Neurourol J       Date:  2015-09-22       Impact factor: 2.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.